Nuklearmedizin 2019; 58(02): 167-168
DOI: 10.1055/s-0039-1683660
Poster
Demenz und Neuroonkologie
Georg Thieme Verlag KG Stuttgart · New York

Glucose metabolism in the basal forebrain of patients with Lewy-body disease assessed by high-resolution digital PET

C Özden
1   University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg
,
L Frings
2   Medical Center – University of Freiburg, Faculty of Medicine, Department of Nuclear Medicine, Freiburg
,
I Apostolova
1   University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg
,
C Lange
3   Charité-Universitätsmedizin Berlin, Department of Nuclear Medicine, Berlin
,
S Klutmann
1   University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg
,
G Adam
1   University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg
,
P Bannas
1   University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg
,
PT Meyer
4   University Hospital Freiburg, Department of Nuclear Medicine, Freiburg
,
M Grothe
5   German Center for Neurodegenerative Diseases, Rostock
,
R Buchert
1   University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2019 (online)

Also available at
 
 

    Ziel/Aim:

    Cognitive decline in Lewy-body disease (LBD), including Parkinson's disease (PD) and dementia with Lewy bodies, is linked to degeneration of the basal forebrain (BF). Assessment of synaptic activity in the BF by FDG PET is hampered by limited spatial resolution of conventional PET. This study tested the feasibility of measuring BF glucose metabolism by high-resolution digital PET (dPET) by (i) testing it for correlation with cortical FDG uptake and (ii) comparing demented and non-demented LBD patients.

    Methodik/Methods:

    Twelve LBD patients (61 – 86 y, 5 demented) fulfilled the eligibility criteria including no evidence of atypical neurodegenerative parkinsonism in FDG dPET (4.0 mm FWHM, reconstructed). Whole-brain stereotactical normalization to MNI space was followed by local stereotactical normalization of a 7 × 7x7 cm box around the BF to a custom-made 1 × 1x1 mm FDG dPET template. Mean FDG uptake in the BF was obtained by a ROI mask predefined in MNI space and then scaled to mean FDG uptake in the pons.

    Ergebnisse/Results:

    Voxelwise testing (uncorr. p < 0.001) for brain-wide correlations with scaled FDG uptake in the BF revealed a large cluster including the basal forebrain, ventral striatal, insular, mesial and ventrolateral frontal areas, and smaller clusters in the motor cortex and the right occipital cortex, but not in the hippocampus. ANOVA with age as covariate showed scaled FDG uptake in the BF to be significantly lower in demented vs. non-demented LBD patients (p = 0.048) and a tendency towards negative correlation with age (p = 0.071).

    Schlussfolgerungen/Conclusions:

    These results suggest that FDG uptake in the BF as assessed by high-resolution FDG dPET is a useful marker of BF degeneration in LBD. More accurate delineation of the BF based on individual high-resolution MRI might be useful to make optimal use of improved spatial resolution of dPET and to correct for possible disease and age-dependent partial volume effects.


    #